{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:30:55Z","timestamp":1793133055907,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization\u2019s List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.<\/jats:p>","DOI":"10.1038\/s41598-020-76258-0","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T06:03:19Z","timestamp":1604556199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20\u00a0years of drug safety surveillance reports"],"prefix":"10.1038","volume":"10","author":[{"given":"Isaac V.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tigran","family":"Makunts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talar","family":"Moumedjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masara A.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Abagyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"76258_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105938","author":"CA Devaux","year":"2020","unstructured":"Devaux, C. A., Rolain, J.-M., Colson, P. & Raoult, D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19?. Int. J. Antimicrob. Agents https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105938 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"76258_CR2","doi-asserted-by":"publisher","first-page":"105923","DOI":"10.1016\/j.ijantimicag.2020.105923","volume":"55","author":"P Colson","year":"2020","unstructured":"Colson, P., Rolain, J.-M. & Raoult, D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int. J. Antimicrob. Agents 55, 105923 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"76258_CR3","doi-asserted-by":"publisher","first-page":"e00293","DOI":"10.1002\/prp2.293","volume":"5","author":"MAA Al-Bari","year":"2017","unstructured":"Al-Bari, M. A. A. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol. Res. Perspect. 5, e00293 (2017).","journal-title":"Pharmacol. Res. Perspect."},{"key":"76258_CR4","unstructured":"Plaquenil [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC (2006)."},{"key":"76258_CR5","unstructured":"Aralen [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC (2013)."},{"key":"76258_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","author":"P Gautret","year":"2020","unstructured":"Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"76258_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao, J., Tian, Z. & Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14, 72\u201373 (2020).","journal-title":"Biosci Trends"},{"key":"76258_CR8","unstructured":"Division, N. HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients. HHS.gov https:\/\/www.hhs.gov\/about\/news\/2020\/03\/29\/hhs-accepts-donations-of-medicine-to-strategic-national-stockpile-as-possible-treatments-for-covid-19-patients.html (2020)."},{"key":"76258_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269\u2013271 (2020).","journal-title":"Cell Res."},{"key":"76258_CR10","unstructured":"ClinicalTrials.gov. (NCT04315896) Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315896?cond=NCT04315896&draw=2&rank=1, (2020)."},{"key":"76258_CR11","unstructured":"ClinicalTrials.gov. (NCT04318015) Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact with COVID-19 Patients (PHYDRA Trial) (PHYDRA). (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318015?term=NCT04318015&draw=2&rank=1, 2020), (2020). ClinicalTrials.gov. (NCT04318444) Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318444?term=NCT04318444&draw=2&rank=1 (2020)."},{"key":"76258_CR12","unstructured":"ClinicalTrials.gov. (NCT04318444) Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318444?term=NCT04318444&draw=2&rank=1 (2020)."},{"key":"76258_CR13","unstructured":"ClinicalTrials.gov. (NCT04321278) Safety and Efficacy of Hydroxychloroquine Associated with Azithromycin in SARS- CoV2 Virus (Alliance Covid-19 Brasil II). (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321278?term=NCT04321278&draw=2&rank=1, 2020), (2020)."},{"key":"76258_CR14","unstructured":"ClinicalTrials.gov. (NCT04308668) Post-exposureProphylaxis\/ Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04308668?term=NCT04308668&draw=2&rank=1 (2020)."},{"key":"76258_CR15","unstructured":"ClinicalTrials.gov. (NCT04304053) Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04304053?term=NCT04304053&draw=2&rank=1, (2020)."},{"key":"76258_CR16","unstructured":"ClinicalTrials.gov. (NCT04316377) Norwegian Coronavirus Disease 2019 Study (NO COVID-19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04316377?term=NCT04316377&draw=2&rank=1, (2020)."},{"key":"76258_CR17","unstructured":"ClinicalTrials.gov. (NCT043032990) Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxy-Chloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04303299?term=NCT04303299&draw=2&rank=1, (2020)."},{"key":"76258_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105955","author":"P Zhai","year":"2020","unstructured":"Zhai, P. et al. The epidemiology, diagnosis and treatment of COVID-19. Int. J. Antimicrob. Agents https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105955 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"76258_CR19","doi-asserted-by":"crossref","unstructured":"Serap, Y. & \u00dcnal, S. Antiviral treatment of COVID-19. Turk. J. Med. Sci. 50, 611\u2013619 (2020).","DOI":"10.3906\/sag-2004-145"},{"key":"76258_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre, C., Roubille, F., Vernhet, H., Jorgensen, C. & Pers, Y.-M. Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature. Drug Saf. 41, 919\u2013931 (2018).","journal-title":"Drug Saf."},{"key":"76258_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.04.016","author":"A Sarayani","year":"2020","unstructured":"Sarayani, A., Cicali, B., Henriksen, C. H. & Brown, J. D. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res. Soc. Adm. Pharm. https:\/\/doi.org\/10.1016\/j.sapharm.2020.04.016 (2020).","journal-title":"Res. Soc. Adm. Pharm."},{"key":"76258_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijcard.2020.03.063","volume":"309","author":"W Tan","year":"2020","unstructured":"Tan, W. & Aboulhosn, J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int. J. Cardiol. 309, 70\u201377 (2020).","journal-title":"Int. J. Cardiol."},{"key":"76258_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.0950","author":"S Shi","year":"2020","unstructured":"Shi, S. et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.0950 (2020).","journal-title":"JAMA Cardiol."},{"key":"76258_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1017","author":"T Guo","year":"2020","unstructured":"Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.1017 (2020).","journal-title":"JAMA Cardiol."},{"key":"76258_CR25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jama.2020.4326","volume":"323","author":"M Arentz","year":"2020","unstructured":"Arentz, M. et al. Characteristics and outcomes of 21 critically Ill patients With COVID-19 in Washington State. JAMA 323, 1612\u20131614 (2020).","journal-title":"JAMA"},{"key":"76258_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475\u2013481 (2020).","journal-title":"Lancet Respir. Med."},{"key":"76258_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1096","author":"RM Inciardi","year":"2020","unstructured":"Inciardi, R. M. et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.1096 (2020).","journal-title":"JAMA Cardiol."},{"key":"76258_CR28","doi-asserted-by":"publisher","unstructured":"Chorin, E. et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine\/Azithromycin. medRxiv 2020.04.02.20047050 (2020) https:\/\/doi.org\/10.1101\/2020.04.02.20047050.","DOI":"10.1101\/2020.04.02.20047050"},{"key":"76258_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01424-5","author":"J-H Zeng","year":"2020","unstructured":"Zeng, J.-H. et al. First case of COVID-19 complicated with fulminant myocarditis: A case report and insights. Infection https:\/\/doi.org\/10.1007\/s15010-020-01424-5 (2020).","journal-title":"Infection"},{"key":"76258_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","volume":"17","author":"Y-Y Zheng","year":"2020","unstructured":"Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y. & Xie, X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 17, 259\u2013260 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"76258_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3163\/1536-5050.95.2.224","volume":"95","author":"V Craigle","year":"2007","unstructured":"Craigle, V. MedWatch: The FDA safety information and adverse event reporting program. J. Med. Libr. Assoc. 95, 224\u2013225 (2007).","journal-title":"J. Med. Libr. Assoc."},{"key":"76258_CR32","doi-asserted-by":"publisher","first-page":"e0195521","DOI":"10.1371\/journal.pone.0195521","volume":"13","author":"T Makunts","year":"2018","unstructured":"Makunts, T., Cohen, I. V., Lee, K. C. & Abagyan, R. Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain. PLoS ONE 13, e0195521 (2018).","journal-title":"PLoS ONE"},{"key":"76258_CR33","doi-asserted-by":"publisher","first-page":"17280","DOI":"10.1038\/s41598-019-53622-3","volume":"9","author":"T Makunts","year":"2019","unstructured":"Makunts, T., Alpatty, S., Lee, K. C., Atayee, R. S. & Abagyan, R. Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Sci. Rep. 9, 17280 (2019).","journal-title":"Sci. Rep."},{"key":"76258_CR34","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1038\/s41598-019-39335-7","volume":"9","author":"T Makunts","year":"2019","unstructured":"Makunts, T., Cohen, I. V., Awdishu, L. & Abagyan, R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci. Rep. 9, 2282 (2019).","journal-title":"Sci. Rep."},{"key":"76258_CR35","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. (2020)."},{"issue":"1","key":"76258_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00265-010-1037-6","volume":"65","author":"E Symonds","year":"2011","unstructured":"Symonds, E. & Matthew, A. A brief guide to model selection, multimodel inference and model averaging in behavioural ecology using Akaike\u2019s information criterion. Behav. Ecol. Sociobiol. 65(1), 13\u201321 (2011).","journal-title":"Behav. Ecol. Sociobiol."},{"key":"76258_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00787-010-0087-7","volume":"19","author":"M Szumilas","year":"2010","unstructured":"Szumilas, M. Explaining odds ratios. J. Can. Acad. Child Adolesc. Psychiatry 19, 227\u2013229 (2010).","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"76258_CR38","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"VL Roger","year":"2011","unstructured":"Roger, V. L. et al. Heart disease and stroke statistics\u20142011 update: A report from the American Heart Association. Circulation 123, e18\u2013e209 (2011).","journal-title":"Circulation"},{"key":"76258_CR39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1144","author":"Z Varga","year":"2017","unstructured":"Varga, Z., Sabzwari, R. A. S. & Vargova, V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: An under-recognized public health issue. Cureus https:\/\/doi.org\/10.7759\/cureus.1144 (2017).","journal-title":"Cureus"},{"key":"76258_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/2042098617690485","volume":"8","author":"A Fanelli","year":"2017","unstructured":"Fanelli, A., Ghisi, D., Aprile, P. L. & Lapi, F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: Latest evidence and clinical implications. Ther. Adv. Drug Saf. 8, 173\u2013182 (2017).","journal-title":"Ther. Adv. Drug Saf."},{"key":"76258_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/BOR.0b013e328363eba3","volume":"25","author":"JS Knight","year":"2013","unstructured":"Knight, J. S. & Kaplan, M. J. Cardiovascular disease in lupus: Insights and updates. Curr. Opin. Rheumatol. 25, 597\u2013605 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"76258_CR42","doi-asserted-by":"publisher","first-page":"e20200652","DOI":"10.1084\/jem.20200652","volume":"217","author":"BJ Barnes","year":"2020","unstructured":"Barnes, B. J. et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 217, e20200652 (2020).","journal-title":"J. Exp. Med."},{"key":"76258_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954","author":"C Zhang","year":"2020","unstructured":"Zhang, C., Wu, Z., Li, J.-W., Zhao, H. & Wang, G.-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105954 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"76258_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3121\/cmr.2013.1197","volume":"12","author":"SV Ittaman","year":"2014","unstructured":"Ittaman, S. V., VanWormer, J. J. & Rezkalla, S. H. The role of aspirin in the prevention of cardiovascular disease. Clin. Med. Res. 12, 147\u2013154 (2014).","journal-title":"Clin. Med. Res."},{"key":"76258_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.04.048","author":"B Long","year":"2020","unstructured":"Long, B., Brady, W. J., Koyfman, A. & Gottlieb, M. Cardiovascular complications in COVID-19. Am. J. Emerg. Med. https:\/\/doi.org\/10.1016\/j.ajem.2020.04.048 (2020).","journal-title":"Am. J. Emerg. Med."},{"key":"76258_CR46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1191\/0961203304lu1023oa","volume":"13","author":"E Tackey","year":"2004","unstructured":"Tackey, E., Lipsky, P. E. & Illei, G. G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13, 339\u2013343 (2004).","journal-title":"Lupus"},{"key":"76258_CR47","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/ard.2004.022681","volume":"64","author":"BJM Ripley","year":"2005","unstructured":"Ripley, B. J. M. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann. Rheum. Dis. 64, 849\u2013853 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"76258_CR48","unstructured":"Basu-Ray, I. & Soos, M. P. Cardiac Manifestations of Coronavirus (COVID-19). In StatPearls (StatPearls Publishing, 2020)."},{"key":"76258_CR49","doi-asserted-by":"publisher","unstructured":"Irabien-Ortiz, \u00c1. et al. Fulminant myocarditis due to COVID-19. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition) (2020) https:\/\/doi.org\/10.1016\/j.rec.2020.04.005.","DOI":"10.1016\/j.rec.2020.04.005"},{"key":"76258_CR50","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","volume":"166","author":"CS Crowson","year":"2013","unstructured":"Crowson, C. S. et al. Rheumatoid arthritis and cardiovascular disease. Am. Heart J. 166, 622-628.e1 (2013).","journal-title":"Am. Heart J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76258-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:22:13Z","timestamp":1670347333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76258-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["76258"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-76258-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.19.20107227","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19199"}}